Form 4: Insider Boost: Thomas Von Koch Increases Stake in DiaMedica Therapeutics

Thomas Von Koch, a Director and 10% owner of DiaMedica Therapeutics Inc., significantly increased his indirect beneficial ownership by purchasing 2,857,142 common shares.

Summary

• Thomas Von Koch, a Director and 10% owner of DiaMedica Therapeutics Inc. (DMAC), acquired additional common shares.
• The transaction occurred on July 23, 2025.
• A total of 2,857,142 common shares were purchased at a price of $3.50 per share.
• Following this transaction, Thomas Von Koch's indirect beneficial ownership stands at 8,383,577 common shares.
• The shares are directly owned by TomEnterprise Private AB and indirectly by Thomas Von Koch through his role as a board member of TomEnterprise AB, with him holding sole voting and disposal power.

Sentiment

Score: 8

Explanation: The significant purchase of shares by a director and 10% owner indicates strong insider confidence, which is a highly positive signal for investors.

Positives

• A significant purchase of 2,857,142 common shares by a Director and 10% owner, Thomas Von Koch, indicates strong insider confidence in the company's future prospects.
• The acquisition price of $3.50 per share suggests management believes the stock is undervalued or poised for growth at this price point.
• The increase in beneficial ownership to 8,383,577 shares reinforces the alignment of insider interests with shareholder value.

Industry Context

This insider transaction reflects a direct investment by a key stakeholder in DiaMedica Therapeutics, a biotechnology company. While not directly indicative of broader industry trends, significant insider purchases can signal confidence in a company's specific pipeline or market position within the biotech sector.

Related Party Transactions

• The transaction involves Thomas Von Koch, a Director and 10% owner, acquiring shares indirectly through entities he controls (TomEnterprise AB and TomEnterprise Private AB), which is a common form of related party transaction for insider ownership changes.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing confidence in the company's stock.
• The transaction reinforces the alignment of interests between a significant owner/director and other shareholders.

Key Dates

Recommendation

The substantial purchase of common shares by a Director and 10% owner, Thomas Von Koch, at a price of $3.50 per share, signals strong insider conviction in DiaMedica Therapeutics Inc.'s valuation and future prospects. Such a significant investment by a key insider often precedes positive developments or reflects a belief that the stock is currently undervalued, making it a compelling 'strong buy' signal for investors.

Keywords

DiaMedica Therapeutics, DMAC, Insider Trading, Form 4, Beneficial Ownership, Thomas Von Koch, Stock Purchase, Biotechnology, Pharmaceuticals, Director, 10% Owner